Vericel to Report First-Quarter 2021 Financial Results on May 5, 2021
April 21 2021 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the following webcast and conference call to discuss its
first-quarter 2021 financial results and business highlights.
What: |
|
Vericel Corporation First-Quarter 2021 Earnings Call |
When: |
|
Wednesday, May 5, 2021 at 8:30am
(EDT) |
Where: |
|
http://investors.vcel.com/events-presentations |
How: |
|
The conference call will be
available live in the Investors section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access the
site at least 15 minutes prior to the scheduled start time in order
to download the required audio software if necessary. Presentation
slides for the conference call will be available on the webcast and
in the Investor Relations section of the Vericel website. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation first-quarter 2021
earnings call. If calling from outside the U.S., please use the
international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until May 5, 2022. A replay of the call will also be available
until 11:30am (EDT) on May 12, 2021 by calling (855) 859-2056, or
from outside the U.S. (404) 537-3406. The conference ID is
9036676.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American commercial rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2021 Vericel
Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2023 to Aug 2024